Back to Search

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

  • Protocol Number: 201904008
  • Principal Investigator: Johanns, Tanner
  • Cancer Types: Early Phase

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions